Pinealon: A Literature Course on What the Studies Report

This page is a structured reading course on Pinealon, organised as six modules. It summarises what the indexed, peer-reviewed literature states about the compound: how it is defined, what mechanisms have been proposed, what outcomes individual studies reported, what those papers say (and do not say) about adverse events, what pharmacokinetic data exist, and what the regulatory picture looks like. Each module closes with an explicit statement of the limits of the evidence, because for this compound the limits are as informative as the findings. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any substance you are considering. Nothing here is a protocol, a recommendation, or a claim of benefit.

Module 1: What Pinealon Is and How It Has Been Studied

Definition and class

Pinealon is the name used in the Russian gerontology and experimental-biology literature for a synthetic tripeptide composed of glutamic acid, aspartic acid and arginine — written as Glu-Asp-Arg and abbreviated EDR in single-letter code. It belongs to the family of very short synthetic peptides (two to four residues) that were developed from earlier work on polypeptide extracts of the pineal gland and other organs, and that are frequently described in that literature as "short peptides" or "peptide bioregulators". Papers that name the sequence directly include the biophysical analysis of Glu-Asp-Arg binding to DNA (PMID 30762356) and a 2020 review of EDR peptide and gene-expression regulation in the context of Alzheimer's disease pathogenesis (PMID 33396470).

Origin and forms

The compound is chemically synthesised, not extracted; it is a defined three-amino-acid sequence rather than a tissue preparation. In the published experiments it appears as a water-soluble peptide added to culture medium, as a ligand in solution for spectroscopic and binding work such as the DNA-interaction study (PMID 30762356), or as a substance administered to laboratory animals in the older Russian-language hypoxia work (PMID 18546825). Some consumer-facing material outside the scientific literature describes capsule or nasal forms; the indexed studies summarised here did not evaluate any finished consumer product.

How it has been studied

The research pattern is narrow and consistent: in vitro cell and tissue cultures, cell-free biophysical binding systems, and a small number of animal experiments, largely from a small group of laboratories publishing in Bulletin of Experimental Biology and Medicine, Advances in Gerontology, Rejuvenation Research and similar journals. Later work extended to fibroblast-derived induced neurons as an ageing model (PMID 39518916).

Limits of the evidence (Module 1): there is no randomised controlled human trial of Pinealon in the verified literature, no independent structural-pharmacology programme, and much of the work comes from overlapping research groups. Naming conventions also vary — "Pinealon", "EDR" and "Glu-Asp-Arg" may or may not refer to identical preparations in every paper, and purity or formulation details are rarely given in abstracts.

Module 2: Mechanism as Described in the Literature

Direct interaction with DNA and chromatin proteins

The dominant mechanistic hypothesis in this literature is that very short peptides can enter cells and nuclei and interact directly with DNA or with chromatin proteins, thereby modulating transcription. Researchers examining Glu-Asp-Arg reported that the peptide's interaction with DNA was sensitive to the presence of mono- and divalent ions, and analysed how ionic conditions shaped complex formation (PMID 30762356). A related study reported that short peptides interacted with FITC-labelled wheat histones and with histone complexes formed with deoxyribooligonucleotides, which the authors framed as evidence for peptide–chromatin binding (PMID 23581987).

Gene expression and protein synthesis

Building on the binding work, a 2020 review proposed that EDR peptide could influence gene expression and protein synthesis in pathways discussed in relation to Alzheimer's disease pathogenesis, and set out that model as a hypothesis for further testing (PMID 33396470). Earlier culture work reported that short peptides altered the expression of signalling molecules in organotypic pineal cell culture (PMID 22803060), and a separate report described stimulation of serotonin expression in cells of the brain cortex (PMID 24909721).

Redox and proliferation

A 2011 report in Rejuvenation Research stated that Pinealon increased cell viability through suppression of free-radical levels and activation of proliferative processes in the model used (PMID 21978084). Related short-peptide work reported effects on irisin, described in that paper as a telomere-length regulator hormone (PMID 26742748).

Limits of the evidence (Module 2): these are mechanistic associations observed in simplified systems. Binding to naked DNA or to plant histones in a cuvette does not establish that the same interaction occurs at physiological concentrations inside a human cell, and none of the verified papers demonstrated a dose–response relationship in a living human being. The proposed epigenetic model remains a hypothesis rather than a validated pathway.

Module 3: Reported Outcomes, Study by Study

The table below lists what each verified report used as its model, what it measured, and what the authors stated they found. Effect statements belong to the cited paper only.

Read together, the pattern is a set of small, mostly single-laboratory experiments reporting cellular and molecular changes. None of these reports measured a clinical outcome such as cognition, sleep quality, or disease progression in humans, and none of them should be read as a promise of any outcome in a person.

Limits of the evidence (Module 3): sample sizes, replication and blinding are rarely described in abstracts; several papers group Pinealon with other short peptides, so effects attributed to "short peptides" may not be specific to Glu-Asp-Arg. Positive-result publication bias is a realistic concern in a small, thematically unified literature, and no independent replication of the neuronal or serotonin findings appears in the verified set.

Module 4: Pinealon Side Effects — What Studies Report

The most important factual statement in this module is negative: the verified literature contains no systematic adverse-event reporting for Pinealon. The cell-culture and biophysical reports were not designed to detect adverse events in an organism. The 2011 viability paper reported increased cell viability and reduced free-radical levels rather than cytotoxicity in the conditions tested (PMID 21978084), and the 2024 induced-neuron study reported protective changes in its ageing model rather than toxicity endpoints (PMID 39518916). An absence of reported harm in such systems is not the same as a demonstrated safety profile; the experiments simply did not ask the question at the level of a whole organism.

Animal work on antihypoxic properties of short peptides likewise focused on functional endpoints rather than on a formal toxicology package (PMID 18546825). For the broader field, a 2026 review of therapeutic peptides in orthopaedics discussed applications alongside challenges including variability in preparations, limited high-quality clinical data and regulatory uncertainty — issues the authors framed as central obstacles for peptide translation (PMID 41490200). Those generic peptide-class concerns — injection-site reactions, immunogenicity, contamination or mislabelling of non-pharmaceutical material, and unknown long-term effects — are discussed in the peptide literature generally, not measured for Pinealon specifically in any verified paper.

Limits of the evidence (Module 4): no human safety trial, no published dose-ranging toxicity study, no long-term follow-up and no pharmacovigilance dataset for this tripeptide appear in the verified literature. Any statement that Pinealon is "well tolerated" would be unsupported by the papers cited on this page, as would any statement that it is unsafe; the honest position is that the safety question is unstudied at the clinical level.

Module 5: Pharmacokinetics Where Data Exist

The verified literature does not contain a pharmacokinetic study of Pinealon in humans or a published absorption, distribution, metabolism and excretion profile in animals. What exists instead is mechanistic and biophysical information relevant to how such a molecule might behave: the ion-dependence of Glu-Asp-Arg binding to DNA suggests that local ionic conditions influence complex formation (PMID 30762356), and histone-binding work indicates interaction with chromatin proteins under the experimental conditions used (PMID 23581987).

Several general features of very short peptides are relevant context: charged tripeptides are typically subject to rapid peptidase cleavage and renal clearance, which is why formulation and delivery research is an active area. A 2020 methodological paper described radiolabelling lipid-based nanocarriers with fluorine-18 for in vivo tracking by PET, illustrating the kind of tracer approach required to generate real biodistribution data (PMID 31982792); that work concerned nanocarrier tracking methodology and did not study Pinealon. Peptide-chemistry work on conformationally restricted analogues of another peptide, angiotensin II, similarly shows how structural modification can change biological activity in a test system (PMID 25420772), but it provides no information about Pinealon.

Limits of the evidence (Module 5): without measured plasma concentrations, half-life, bioavailability by any route, or evidence of central nervous system penetration in a living organism, it is not possible to connect the concentrations used in culture experiments to any exposure in a person. Statements about how much reaches the brain, or how long effects persist, are not supported by the verified literature.

Module 6: Regulatory Status, Stated Factually

There is no United States Food and Drug Administration–approved drug product whose active ingredient is Pinealon or Glu-Asp-Arg, and no European Medicines Agency marketing authorisation for it. The compound is not a recognised dietary-supplement ingredient with an established regulatory dossier in the US, and material offered under this name is commonly labelled for research use only — a designation meaning the substance is intended for laboratory investigation and is not authorised for administration to humans. Research-use-only labelling carries no requirement for the identity, purity, sterility or potency testing applied to approved medicines.

Compounding pharmacies in the US may prepare medicines from bulk drug substances only within the statutory framework governing compounding, which limits the substances eligible for use; peptides lacking approved-drug status or eligible-substance listing fall outside that framework. The 2026 orthopaedic peptide review discussed regulatory uncertainty and inconsistent product quality as recurring challenges across the therapeutic-peptide field, alongside the need for higher-quality clinical trials (PMID 41490200). Much of the Pinealon literature originates in the Russian Federation, where regulatory categories for peptide preparations differ from those in the US and EU; the clinical status of a product in one jurisdiction does not transfer to another. This section is general regulatory information, not legal advice.

Limits of the evidence (Module 6): regulatory status changes over time and by country, and the verified scientific papers do not adjudicate legal questions. Readers with regulatory or legal questions should consult qualified professionals in their own jurisdiction.

What the Studies Did Not Test

Across the verified literature, the following were never examined for Pinealon:

• Clinical outcomes in humans — no randomised, placebo-controlled trial measuring cognition, memory, sleep, mood or disease progression appears in the verified set; the neuronal and cortical findings were cell-based (PMID 39518916, PMID 24909721).
• Dose–response in an organism — no verified paper established a relationship between an administered amount and a measured human endpoint.
• Safety and toxicology — no formal adverse-event surveillance, organ-toxicity or long-term exposure data, as noted in Module 4.
• Pharmacokinetics in humans — no absorption, half-life or brain-penetration measurements; tracer methodology exists for other systems (PMID 31982792).
• Specificity versus related short peptides — several reports tested short peptides as a group rather than isolating Glu-Asp-Arg (PMID 22803060, PMID 26742748).
• Interactions — no studies of combination with medicines or other peptides.

A reasonable summary of the field is that Pinealon has an interesting mechanistic hypothesis grounded in peptide–DNA and peptide–histone binding chemistry (PMID 30762356, PMID 33396470), a modest set of cell-culture findings, and essentially no clinical evidence base. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

References

• Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes (Rejuvenation Research, 2011)
• Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture (Bulletin of Experimental Biology and Medicine, 2011)
• Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides (Biochemistry (Moscow), 2013)
• Short peptides stimulate serotonin expression in cells of brain cortex (Bulletin of Experimental Biology and Medicine, 2014)
• Short Peptides and Telomere Length Regulator Hormone Irisin (Bulletin of Experimental Biology and Medicine, 2016)
• Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction (The Journal of Physical Chemistry B, 2019)
• EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease (Molecules, 2020)
• Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes (International Journal of Molecular Sciences, 2024)
• Investigation of antihypoxic properties of short peptides (Advances in Gerontology, 2008)
• Radiolabelling of lipid-based nanocarriers with fluorine-18 for in vivo tracking by PET (Colloids and Surfaces B: Biointerfaces, 2020)
• Angiotensin II restricted analogs with biological activity in the erythrocytic cycle of Plasmodium falciparum (Journal of Peptide Science, 2015)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)